Fundraising Fox
/Companies
Sign in

Denovo Sciences

Plymouth, US · Founded 2011 · Delaware corporation · 2 known investors

Find your way into Denovo Sciences

Sign up to see every warm intro you have to Denovo Sciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Denovo Sciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Denovo Sciences develops an AI platform for structure-based small-molecule drug discovery, using generative algorithms to design candidate molecules de novo within a target's binding pocket and predict their synthesizability and drug-likeness. It runs its own drug discovery programs and partners with others to identify small-molecule drug candidates, including work on broad-spectrum influenza inhibitors.

AI & Machine LearningBiotechDeep TechHealthtech

Founders & leadership

Denovo Sciences was founded in 2011 by Hovakim Zakaryan, Vardan Harutyunyan, and Mher Matevosyan.

HZHovakim Zakaryan
Hovakim ZakaryanCo-Founder & CEO
VHVardan Harutyunyan
Vardan HarutyunyanCo-Founder & CAIO
MMMher Matevosyan
Mher MatevosyanCo-Founder & CTOMher Matevosyan is co-founder and CTO of Denovo Sciences, which develops an AI platform for structure-based small-molecule drug discovery using generative algorithms. He has research experience in generative adversarial networks and reinforcement learning.
PG
Priyardarshini GogoiExecutive
KH
Kalyan HandiqueNamed on SEC filing

Board

JB
Jack BallBoard director
DD
Dr. David ParkinsonBoard director
WY
Walter Young, Jr.Board director
RN
Roger NewtonBoard director
TM
Timothy MaylebenBoard director

Investors · 2

Triple Ventureslisted by Triple VenturesMalibu

Reported raises · per SEC filings

Form D private placements

$39M disclosed across 7 rounds · 2014–2019

▶$5.1MraisedDec 2019 · 25 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Kalyan HandiqueExecutive Officer, Director
  • John StarkExecutive Officer, Director
  • Walter Young, Jr.Director
  • Timothy TricheDirector
  • Gregg FergusDirector
  • Richard SharpDirector
  • Roger NewtonDirector
Offering amount
$15.3M
Amount sold
$5.1M
Sales commissions
$60K
Placement agents
Evercore Group L.L.C.
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$18.5MraisedNov 2018 · 44 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John MillerDirector
  • Jack BallDirector
  • Roger NewtonDirector
  • Kalyan HandiqueExecutive Officer, Director
  • John StarkExecutive Officer, Director
  • Walter Young, Jr.Director
  • Gregg FergusDirector
Offering amount
$21.5M
Amount sold
$18.5M
First sale
Nov 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedMay 2018 · 28 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Kalyan HandiqueExecutive Officer, Director
  • John StarkExecutive Officer, Director
  • John MillerDirector
  • Walter Young, Jr.Director
  • Gregg FergusDirector
  • Roger NewtonDirector
  • Jack BallDirector
Offering amount
$5M
Amount sold
$2.4M
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.9MraisedOct 2017 · 40 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jack BallDirector
  • Priyardarshini GogoiExecutive Officer, Director
  • Walter Young, Jr.Director
  • John MillerDirector
  • Kalyan HandiqueExecutive Officer, Director
  • Roger NewtonDirector
Offering amount
$7.9M
Amount sold
$7.9M
First sale
Oct 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedSep 2016 · 23 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Priyardarshini GogoiExecutive Officer, Director
  • Roger NewtonDirector
  • Kalyan HandiqueExecutive Officer, Director
  • Jack BallDirector
  • Walter Young, Jr.Director
Offering amount
$3.5M
Amount sold
$1.5M
First sale
Sep 2016
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedSep 2015 · 19 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Priyardarshini GogoiExecutive Officer, Director
  • Jack BallDirector
  • Kalyan HandiqueExecutive Officer, Director
  • Dr. David ParkinsonDirector
  • Walter Young, Jr.Director
  • Roger NewtonDirector
Offering amount
$3M
Amount sold
$1.3M
First sale
Sep 2015
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedDec 2014 · 21 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Dr. David ParkinsonDirector
  • Priyardarshini GogoiExecutive Officer, Director
  • Timothy MaylebenDirector
  • Kalyan HandiqueExecutive Officer, Director
  • Walter Young, Jr.Director
Offering amount
$2.3M
Amount sold
$2.3M
First sale
Oct 2014
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

DenovaiDenovAI Biotech uses artificial intelligence and computational molecular biophysics to design proteins de novo, building platforms for rapid antibody discovery and bespoke high-affinity binders. The company targets therapeutic and diagnostic applications, including antibodies, peptide biologics, and diagnostic reporters for drug discovery.

Companies working in the same space as Denovo Sciences.

Frequently asked questions

What does Denovo Sciences do?
Denovo Sciences develops an AI platform for structure-based small-molecule drug discovery, using generative algorithms to design candidate molecules de novo within a target's binding pocket and predict their synthesizability and drug-likeness. It runs its own drug discovery programs and partners with others to identify small-molecule drug candidates, including work on broad-spectrum influenza inhibitors.
Who founded Denovo Sciences?
Denovo Sciences was founded by Hovakim Zakaryan, Vardan Harutyunyan, Mher Matevosyan in 2011.
Who are Denovo Sciences's investors?
Denovo Sciences's investors include Granatus Ventures, Triple Ventures.
How much funding has Denovo Sciences raised?
Denovo Sciences has disclosed $39M raised across 7 rounds.
Where is Denovo Sciences headquartered?
Denovo Sciences is headquartered in Plymouth, US.